Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Follow-Up Questions
Absci Corp의 CEO는 누구입니까?
Mr. Sean Mcclain은 2011부터 회사에 합류한 Absci Corp의 Chief Executive Officer입니다.
ABSI 주식의 가격 성능은 어떻습니까?
ABSI의 현재 가격은 $3.94이며, 전 거래일에 decreased 0.25% 하였습니다.
Absci Corp의 주요 사업 주제나 업종은 무엇입니까?
Absci Corp은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Absci Corp의 시가총액은 얼마입니까?
Absci Corp의 현재 시가총액은 $589.1M입니다
Absci Corp는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 8명의 분석가가 Absci Corp에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 10명의 매수, 1명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
